Is the Affinity Column–Mediated Immunoassay Method Suitable as an Alternative to the Microparticle Enzyme Immunoassay Method as a Blood Tacrolimus Assay?

Ju, Man Ki; Chang, Hojin; Kim, H.J.; Huh, Kyu Ha; Ahn, Hyung Joon; Kim, M.S.; Kim, S.I.; Kim, Y.S.

doi:10.1016/j.transproceed.2008.04.019

Cited by 19 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefits of ACMIA are a lighter workload and high throughput (4). Two recent studies reported a high correlation between the whole blood CyA and Tac concentrations measured by ACMIA and alternative immunoassays (8,9).…”

Section: Discussionmentioning

confidence: 99%

“…Because the Tac measurement by LC-MS/MS is both labor intensive and time consuming, several alternative techniques are currently preferred, including the microparticle enzyme-linked immunoassay, enzyme-multiplied immunoassay, chemiluminescent microparticle immunoassay, and antibody-conjugated magnetic immunoassay (ACMIA) method (4)(5)(6). An appropriate analytical method is important for therapeutic drug monitoring.…”

Section: Introductionmentioning

confidence: 99%

“…An appropriate analytical method is important for therapeutic drug monitoring. The ACMIA method is a monoclonal antibody-based immunoassay that requires no pretreatment, and the procedure is highly automated (4). Therefore, the ACMIA method is widely favored for routine monitoring of immunosuppressive drug concentrations.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Delayed False Elevation of Circulating Tacrolimus Concentrations after Cord Blood Transplantation in a Patient with Myelodysplastic Syndrome

et al. 2014

View full text Add to dashboard Cite

We herein describe the case of a 60-year-old man with a history of Behçet's disease and myelodysplastic syndrome who received cord blood transplantation (CBT). The patient was given anti-thymocyte globulin conditioning and tacrolimus to prevent graft-versus-host disease. Two months after CBT, his blood Tac concentration measured by an antibody-conjugated magnetic immunoassay (ACMIA) was found to have increased >4-fold, even after the Tac treatment was stopped. This false response was caused by the interference of endogenous heterophilic antibodies with ACMIA. Therefore, physicians must be aware of possible false ACMIA results for patients with a history of autoimmune disease and/or treated by xenogeneic antibody therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Delayed False Elevation of Circulating Tacrolimus Concentrations after Cord Blood Transplantation in a Patient with Myelodysplastic Syndrome

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that the results of the ACMIA correlate with those of alternative immunoassays. 5,6 Additionally, compared with other immunoassays, the ACMIA does not interfere with hematocrit values, and pretreatment is not required. However, in the last decade, some cases have been described in which the blood tacrolimus concentrations as measured by the ACMIA revealed falsely elevated drug concentrations in kidney, liver, and heart transplant recipients.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Taguchi

Ohmura²,

Ohya³

et al. 2014

Exp Clin Transplant

View full text Add to dashboard Cite

Safe use of tacrolimus relies on regular whole-blood drug monitoring. Of the methods used to assess whole-blood tacrolimus concentration, antibodyconjugated magnetic immunoassay is mostly used for therapeutic drug monitoring because it requires only a minimal sample preparation and no pretreatment procedure. However, several cases recently have been reported in which abnormally false elevated tacrolimus concentrations were measured by antibody-conjugated magnetic immunoassay (>15 ng/mL), despite the absence of clinical symptoms.We present 2 cases of falsely detected tacrolimus concentrations that did not show abnormally high values within the therapeutic range. Whole-blood tacrolimus concentrations obtained by antibodyconjugated magnetic immunoassay showed wellcontrolled concentrations (approximately 2-8 ng/mL), whereas those obtained by another immunoassay and in washed erythrocytes were below the assay range (< 1.2 ng/mL). Thus, antibody-conjugated magnetic immunoassay can elicit falsely positive results of tacrolimus concentrations, even though they are within the therapeutic range.

show abstract

“…Immunoassays are highly suited to a routine laboratory with excellent automation and high throughput [5,6]. The major weakness of this technology is the non-specific binding of the antibody to tacrolimus metabolites and endogenous compounds [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic drug monitoring of tacrolimus by liquid chromatography–tandem mass spectrometry: Is it truly a routine test?

Taylor

Franklin

Tai

et al. 2012

Journal of Chromatography B

View full text Add to dashboard Cite

Is the Affinity Column–Mediated Immunoassay Method Suitable as an Alternative to the Microparticle Enzyme Immunoassay Method as a Blood Tacrolimus Assay?

Cited by 19 publications

References 10 publications

Delayed False Elevation of Circulating Tacrolimus Concentrations after Cord Blood Transplantation in a Patient with Myelodysplastic Syndrome

Delayed False Elevation of Circulating Tacrolimus Concentrations after Cord Blood Transplantation in a Patient with Myelodysplastic Syndrome

Untitled

Therapeutic drug monitoring of tacrolimus by liquid chromatography–tandem mass spectrometry: Is it truly a routine test?

Contact Info

Product

Resources

About